1Tumlin JA, Lohavichan V, Hennigar R. Crescentic, proliferative IgA nephropathy: clinical and histological response to methylpredniselone and intravenous cyclophosphamide[J]. Nephrol Dial Transplant, 2003,18(7): 1321-1329.
6Ponticelli C, Zucchelli P, Imbasciati E, et al. Controlled trial of methylprednisolonc and chlorambucil in idiopathic membranous nephropathy[J].N Engl Med, 1984,310(15):946-950.
7Ponticelli C, Zucchelli P, Passerini P, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy[J]. Kidney Int,1995,48(5): 1 600-1 604.
8Ponticelli C, Altieri P, Scolari F, et al, A randomized study comparing methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy[J], J Am Soy Nephrol, 1998,9(3):444-450.
10Miller G, Zimmerman R, Radhakrishnank, et al. Use of mycophenolate mofetil in resistant membranous nephropathy [J]. Am J Kidney Dis,2000,36(2):250-256.
二级参考文献27
1Austin HA. Therapy of lupus nephritis: controlled trial of prednisone and cytoxic drugs. New Engl J Med, 1986, 314:614-619.
2Vasquez S, Kavanaugh AF, Schneider NR, et al. Acute nonlymphocytic leukemia after treatment of systemic lupus erythematosus with immunosuppressive agents. J Rheumatol,1992, 19: 1625.
3Glicklich D, Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis, 1998, 32: 318-322.
4Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med, 2000,343: 1156-1162.
